Filing Flows › Opus Genetics (IRD) › Q1 2025
Opus Genetics (IRD) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
Opus Genetics (IRD) reported revenue of $4.4M for the first quarter 2025 (Q1 2025), +155% from a year earlier and +2% from the quarter before. Operating margin was -227.2%, net loss $8.2M (187.5% of revenue).
Opus Genetics, Q1 2025: revenue $4.4M (+155% year over year), operating margin -227.2%, net loss $8.2M, operating cash flow −$9.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.4M | +2% | +155% |
| Operating profit | −$9.9M | — | — |
| Net earnings | −$8.2M | — | — |
| Operating cash flow | −$9.0M | — | — |
What changed
Revenue was $4.4M in Q1 2025, up 155% year over year and up 2% from the previous quarter.
Operating costs exceeded revenue by $9.9M, an operating margin of -227.2%. Total costs grew 52% against revenue growth of 155%. The fastest-growing cost line was Research & development (+67%). The quarter ended with a net loss of $8.2M, narrower than the previous quarter's $35.1M loss. Non-operating items added $1.7M, -21% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$9.0M. Non-cash charges added back $13K of depreciation and $913K of share-based compensation. Working capital and other items used $1.7M.
Questions
What was Opus Genetics' revenue in the first quarter 2025?
Opus Genetics (IRD) reported revenue of $4.4M for the first quarter 2025 (Q1 2025), +155% from a year earlier and +2% from the quarter before.
Was Opus Genetics profitable in the first quarter 2025?
Operating loss was $9.9M (-227.2% of revenue) and net loss $8.2M.
Source: Opus Genetics 10-Q on SEC EDGAR.